To further elucidate the role and value of craniocerebral radiotherapy in the treatment of patients with lung cancer, we used the PSM method to minimize the impact of these factors, especially the impact of differences in lung-molGPA, which could more accurately compare the effects of EGFR-TKIs combined with craniocerebral radiotherapy and EGFR-TKI alone (36–38). This evidence concerns the gene EGFR and lung cancer.